GENFIT: PUBLICATION OF THE 2018 REGISTRATION DOCUMENT
27 Février 2019 - 9:13PM
GENFIT:
PUBLICATION OF THE 2018 REGISTRATION DOCUMENT
Lille (France),
Cambridge (Massachusetts, United States), February 27, 2019 -
GENFIT (Euronext: GNFT - ISIN: FR0004163111), a late-stage
biopharmaceutical company dedicated to the discovery and
development of innovative therapeutic and diagnostic solutions in
metabolic and liver related diseases, announces today the filing of
its 2018 Registration Document with the Autorité
des marchés financiers (AMF).
The French-language document is
available to the public free of charge in accordance with
applicable regulations and may be viewed at and downloaded from
GENFIT's website at the following address: www.genfit.com.
The 2018 Registration Document is also available on the AMF
website: www.amf-france.org
GENFIT's 2018 Registration
Document includes, in particular, the annual financial report, the
annual Board of Directors' management report, the Board of
Directors' report on corporate governance, the Statutory Auditors'
reports on annual and consolidated financial statements and the
description of the fees paid to the Statutory Auditors.
About
GENFIT
GENFIT is a late-stage
biopharmaceutical company dedicated to the discovery and
development of innovative therapeutic and diagnostic solutions in
metabolic and liver related diseases where there are considerable
unmet medical needs, corresponding to a lack of approved
treatments. GENFIT is a leader in the field of nuclear
receptor-based drug discovery with a rich history and strong
scientific heritage spanning almost two decades. Its most advanced
drug candidate, elafibranor, is currently being evaluated in a
pivotal Phase 3 clinical trial ("RESOLVE-IT") as a potential
treatment for nonalcoholic steatohepatitis (NASH). NASH is
considered by regulatory authorities as a medical emergency because
of its potentially severe consequences, although often asymptomatic
until late stages, and because its prevalence is on the rise.
Elafibranor has obtained positive preliminary results in a Phase 2
clinical trial in primary biliary cholangitis, a severe chronic
liver disease. As part of GENFIT's comprehensive approach to
clinical management of NASH patients, GENFIT is also developing a
new, non-invasive and easy-to-access blood-based in vitro diagnostic, or IVD, test to identify patients
with NASH who may be appropriate candidates for drug therapy. With
facilities in Lille and Paris, France, and Cambridge, MA, USA,
GENFIT has approximately 150 employees. GENFIT is a public company
listed in compartment B of Euronext's regulated market in Paris
(Euronext: GNFT - ISIN: FR0004163111). www.genfit.com
FORWARD LOOKING
STATEMENT/DISCLAIMER
This press release contains
certain forward-looking statements. Although the Company believes
its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those expressed in, or implied or projected by, the
forward-looking statements. These risks and uncertainties include,
among other things, the uncertainties inherent in research and
development, including related to safety, biomarkers, progression
of, and results from, its ongoing and planned clinical trials,
including its RESOLVE-IT Phase 3 trial, review and approvals by
regulatory authorities, such as the FDA or the EMA, of its drug and
diagnostic candidates, the success of any in-licensing strategies,
the Company's continued ability to raise capital to fund its
development, as well as those discussed or identified in the
Company's public filings with the AMF, including those listed in
Section 4 "Main Risks and Uncertainties" of the Company's 2018
Registration Document filed with the French Autorité des Marchés
Financiers on February 27, 2019 under n° D.19-0078, which is
available on GENFIT's website (www.GENFIT.com) and on the website
of the AMF (www.amf-france.org) and as updated by the 2018 Half
Year Business and Financial Report and available on the Investors
page of GENFIT's website. Other than as required by applicable law,
the Company does not undertake any obligation to update or revise
any forward-looking information or statements. This press release
and the information contained herein do not constitute an offer to
sell or a solicitation of an offer to buy or subscribe to shares in
GENFIT in any country. This press release has been prepared in both
French and English. In the event of any differences between the two
texts, the French language version shall supersede.
CONTACT
GENFIT |
Investors
Naomi EICHENBAUM - Investor
Relations | Tel: +1 (617) 714 5252 | investors@genfit.com
PRESS RELATIONS
| Media
Hélène LAVIN - Press relations |
Tel: +333 2016 4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène
Avinée, 59120 Loos - FRANCE | +333 2016 4000 |
www.GENFIT.com
2019.02.27 PR GENFIT Publication of
RD
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GENFIT via Globenewswire
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024